SMO
protein-codingsmoothened, frizzled class receptor, the group of G protein-coupled receptors, Class F frizzled
Gene summary
The protein encoded by this gene is a G protein-coupled receptor that interacts with the patched protein, a receptor for hedgehog proteins. The encoded protein tranduces signals to other proteins after activation by a hedgehog protein/patched protein complex. [provided by RefSeq, Jul 2010]
- SMOH
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~24.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0009436
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0011134
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0018309
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0007959
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0011134
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:1030005
Submitter: ClinGen
The smoothened frizzled class receptor is encoded by the *SMO *gene and is located at 7q32.1. Multiple disease entities have been reported in association with this gene. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, there was evidence of differences in molecular mechanism, phenotypic spectrum, and mode of inheritance. Therefore, Curry-Jones syndrome, somatic mosaic (MIM:601707) and Happle-Tinschert Syndrome were lumped, while Pallister-Hall-like syndrome (OMIM:241800) was split. Mosaic SMO syndrome is caused by a postzygotic mutation (c.1234 C>T p.Leu412Phe) in the *SMO *gene. The altered amino acid, Leu412, localizes to transmembrane helix 5 of *SMO* within one of three pivot regions that are likely to have a key role in the conformational changes required for receptor activation (PMID 27236920). This mutant allele is present at levels below 50% in samples and is not reliably detected in blood or saliva (PMID 27236920). This gene-disease relationship was first described in 2016 (PMID 27236920 Twigg et al., 2016). Sixteen probands reported in six publications were included in this curation (PMIDs: 27236920, 31825089, 31607746, 29335739, 31120550, 36707059). This gene-disease relationship is also supported by biochemical assays, functional alteration, expression, and non-human model organisms (PMIDs: 12192414, 15618519, 21859383, 24859340, 15520185, 15107405). In summary, there is definitive evidence supporting the relationship between *SMO* and mosaic SMO syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings. This classification was approved by the Craniofacial Malformations Gene Curation Expert Panel on the meeting date 11/16/2023 (SOP Version 9).
Inheritance Pattern: AR
Disease ID:MONDO:0009436
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0009436
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0009436
Submitter: ClinGen
The SMO gene is located on chromosome 7 at 7q32.1 and encodes a G protein-coupled receptor that interacts with the patched protein, a receptor for hedgehog proteins. SMO was first reported in relation to autosomal recessive Pallister-Hall-like syndrome in 2018 by Rubino et al. (PMID: 30497210). Pallister-Hall-like syndrome is a pleiotropic disorder characterized by postaxial polydactyly, hypothalamic hamartoma, cardiac and skeletal anomalies, craniofacial dysmorphisms, and language delay. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, the ClinGen Craniofacial Malformations GCEP found differences in inheritance pattern and phenotypic variability between the disease assertions. Therefore, the following disease entities have been split into multiple disease entities, Curry-Jones syndrome (OMIM:601707) and Pallister-Hall-like syndrome (OMIM:241800). The split curation for Curry-Jones syndrome has been curated separately by the Craniofacial Malformations GCEP. Here, the Syndromic Disorders GCEP has curated the relationship between SMO and Pallister-Hall-like syndrome. Seven variants (5 missense, 1 nonsense, and 1 splicing variants) that have been reported in five probands in two publications (PMIDs: 32413283, 35034092) are included in this curation. This gene-disease relationship is also supported by expression, protein-protein interactions, biochemical function, and animal model evidence (PMIDs: 29558958, 11440720, 27801979, 29571613, 32413283). In summary, there is moderate evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged.This classification was approved by the ClinGen Syndromic Disorders GCEP on the meeting date October 20th, 2023 (SOP Version 10).
Inheritance Pattern: AR
Disease ID:MONDO:0009436
Submitter: G2P
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Endocrine; Musculoskeletal; Neurologic
Intervention: Cardiovascular
Rationale: The condition can involve congenital cardiac anomalies, and awareness may allow early management; Interventions related to endocrine abnormalities may be beneficial; Surgical interventions related to hypothalamic hamartoma may be indicated
Comments: Somatic variants can result in Curry-Jones syndrome
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to SMO variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_005631.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 7 | 25 | 2 | 34 | ||
| missense | 6 | 3 | 134 | 9 | 2 | 154 |
| nonsense | 1 | 1 | 2 | |||
| start loss | 0 | |||||
| frameshift | 1 | 3 | 4 | |||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 7 | 4 | 145 | 34 | 4 | 194 |
Highest pathogenic variant AF is 0.000026651196
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_005622.1 | 12 | MANE Select | |
| Ensembl | ENSP00000249373.3 | 12 | MANE Select | |
| Ensembl | ENSP00000418720.2 | 4 | Standard | |
| Ensembl | ENSP00000420749.1 | 3 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| smo | Danio rerio | Structure: retinal ganglion cell Quality: process quality abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Axon guidance - Homo sapiens (human)
- Basal cell carcinoma - Homo sapiens (human)
- Proteoglycans in cancer - Homo sapiens (human)
- Pathways in cancer - Homo sapiens (human)
- Hedgehog signaling pathway - Homo sapiens (human)
Biological Process
- negative regulation of transcription by RNA polymerase II
- vasculogenesis
- osteoblast differentiation
- in utero embryonic development
- cell fate specification
Molecular Function
- G protein-coupled receptor activity
- patched binding
- protein binding
- drug binding
Cellular Component
- Golgi apparatus
- plasma membrane
- caveola
- cilium
- integral component of membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000249373
- Coding exons
- 12
- Length
- 24674
- Individuals with no LoFs
- 125711
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 37
- Defined
- 125748
- p
- 0.000147
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.90 | 345 | 459 | 0.751 | 0.0000287 | 5019 |
| Missense (PolyPhen) | 78 | 130.22 | 0.59899 | 1386 | ||
| Synonymous | 0.0952 | 183 | 185 | 0.991 | 0.0000115 | 1657 |
| Loss of Function | 3.08 | 17 | 37.3 | 0.456 | 0.00000223 | 344 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000062 | 0.000062 | rare |
| Latino/Admixed American | 0.00029 | 0.00029 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.000054 | 0.000054 | rare |
| Finnish | 0.000093 | 0.000092 | rare |
| European (Non-Finnish) | 0.00016 | 0.00016 | rare |
| South Asian | 0.000098 | 0.000098 | rare |
| Other | 0.00033 | 0.00033 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7, GLI2 and GLI3 in the cilia (PubMed:19592253). Interacts with DLG5 at the ciliary base to induce the accumulation of KIF7 and GLI2 at the ciliary tip for GLI2 activation (By similarity). {ECO:0000250|UniProtKB:P56726, ECO:0000269|PubMed:19592253}.;
- Disease
- DISEASE: Curry-Jones syndrome (CRJS) [MIM:601707]: A multisystem disorder characterized by patchy skin lesions, polysyndactyly, diverse cerebral malformations, unicoronal craniosynostosis, iris colobomas, microphthalmia, and intestinal malrotation with myofibromas or hamartomas. {ECO:0000269|PubMed:24859340, ECO:0000269|PubMed:27236920}. Note=The disease is caused by mutations affecting the gene represented in this entry. 8 individuals have been identified with the disease-causing mutation Phe-412 and all were mosaic. The mutation could not be reliably detected in blood, greatest success rates were obtained with affected tissues obtained by invasive procedures. It is thought that the mutation has arisen postzygotically early during embryonic development (PubMed:27236920). This mutation has also been identified in ameloblastoma, medulloblastoma, meningioma, and basal cell carcinoma, and has been reported as the oncogenic driver in some of these tumors (PubMed:24859340). {ECO:0000269|PubMed:24859340, ECO:0000269|PubMed:27236920}.;
Recessive Scores
- pRec
- 0.412
Intolerance Scores
- LoFtool
- 0.242
- RVIS EVS
- -0.57
- RVIS percentile EVS
- 18.9
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.963
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |